.jpg?format=webp&width=780)
An expanded genomic profiling (EGP) program was conducted on 187 patients with advanced colorectal cancer (CRC) to assess the prevalence of genomic alterations and the percentage of patients included in genomically guided clinical trials. Next-generation sequencing (NGS) analysis was performed on formalin-fixed paraffin-embedded tumor samples to identify mutations, copy number alterations, and fusions, as defined by the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). ESCAT-defined alterations were found in 28.8% of patients, with most classified in ESCAT III and IV. The final rate of inclusion into genomically guided clinical trials was 2.7%. While EGP programs are feasible, further efforts are needed to increase the rate of patients treated with genomically guided therapies
Like
Save
Share